# CORRECTION Open Access

# Correction: Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients

Zengwei Tang<sup>1,2,3,5</sup>, Yuan Yang<sup>4</sup>, Qi Zhang<sup>1,2,3,5</sup> and Tingbo Liang<sup>1,2,3,5\*</sup>

## Correction: Clinical Epigenetics (2023) 15:13 https://doi.org/10.1186/s13148-022-01413-5

Following publication of the original article [1], the authors noticed an error in the Supplementary file. The online Additional File 4 does not belong to "the Supplementary file". The typesetter has incorrectly uploaded Fig. 4 instead of Additional file 4: Fig. S4. This has been replaced with the correct file by publishing this correction. The ten pairs of HCC tissue samples used for immunoblotting (Fig. 2B) are the same as in our previous work [1]. The COL12A1 and NUP37 bands for the four pairs of HCC samples were collected from the same gel as well.

The original article has been corrected.

The original article can be found online at https://doi.org/10.1186/s13148-022-01413-5.

\*Correspondence:

Tingbo Liang

liangtingbo@zju.edu.cn

- <sup>1</sup> Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China
- <sup>2</sup> Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China
- <sup>3</sup> Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou 310003, Zhejiang, China
- <sup>4</sup> Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

# **Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13148-023-01455-3.

Additional file 4.

Published online: 21 March 2023

### Reference

 Tang Z, Yang Y, Chen W, et al. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. J Transl Med. 2022;20(1):49.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data

<sup>&</sup>lt;sup>5</sup> Zhejiang University Cancer Center, Hangzhou 310058, Zhejiang, China